Rezultati pretraživanja
  1. prije 20 minuta

    Recent Research Analysts’ Ratings Changes for Regenxbio

  2. prije 54 minute

    Zacks Investment Research Downgrades Regenxbio to Sell

  3. prije 11 sati

    This one is getting bipolar : ) 4.06 % change recently

  4. 3. velj

    Bought @ "Gann 4" [... front-running the market... but supported by fundamentals]. Looking OK... even in this adverse market.

  5. 3. velj

    Expecting huge recovery on oversold beaten down best in class and most promising Will only get higher from here if coronavirus stays relatively contained in US and outside China. and small plays in , data expected

    1 korisnik označava da mu se sviđa
  6. 2. velj

    Which is best trading strategy in for now?

    Which is best trading strategy in for now (week of 1/27/2020)?
    1 reply 1 korisnik označava da mu se sviđa
  7. 1. velj

    Regenxbio Earns “Buy” Rating from Chardan Capital

  8. 31. sij

    Regenxbio Stock Rating Reaffirmed by Chardan Capital

  9. 30. sij

    Here's a sneak peak of some of our Top Stock Picks for today. Start your free Barchart Premier trial to access the full list daily.

    1 korisnik označava da mu se sviđa
  10. 29. sij

    Biotech updates 01/29: discont HBV trial -22% offerings Orphan Drug Desig +13% Pipeline updates

    4 proslijeđena tweeta 6 korisnika označava da im se sviđa
  11. 29. sij

    Another one was that looked pennant like then broke back into pattern, currently a channel up

  12. 29. sij

    How much royalties will receive?

    1 reply 1 korisnik označava da mu se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  13. 29. sij

    3rd Qtr Royalties on $160M Sales ~ $9.2M 4th Qtr Royalties on $200M Sales ~ $13.6M (Estimated) 100 Patients/Qtr = $720M in 2020 sales - Royalties = $54M without any growth + $80M Milestone after 1st $1B in sales = ~ $134M (2020) not too shabby

    1 proslijeđeni tweet 1 korisnik označava da mu se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.